Orexo: invitation to presentation of the Q2 2024 Interim Report
Orexo will release its Q2 2024 Interim Report on July 17, 2024, at 8 am CET. A presentation for analysts, investors, and media will follow at 2 pm the same day, featuring CEO Nikolaj Sørensen and CFO Fredrik Järrsten. The presentation will cover the latest developments and include a Q&A session. Interested parties can attend either via teleconference or webcast, with registration details and relevant links provided in the press release. Presentation materials will be available on Orexo's website under the Investors/Reports, Presentations section prior to the event.
- Orexo demonstrates transparency by announcing an upcoming detailed presentation of Q2 2024 performance.
- Engagement with analysts, investors, and media through a Q&A session may foster increased investor confidence.
- No preliminary financial data, such as earnings or revenue estimates, are provided ahead of the report release.
UPPSALA, Sweden , July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET. The same day at 2 pm, analysts, investors, and media are invited to attend a presentation where Nikolaj Sørensen, CEO, and Fredrik Järrsten, CFO, will present the latest development and host a Q&A.
To attend via teleconference where you can ask questions verbally use this link: https://conference.financialhearings.com/teleconference/?id=50048737
When registered you will be provided phone numbers and a conference ID to access the conference.
To attend via webcast: https://ir.financialhearings.com/orexo-q2-report-2024
Prior to the event the presentation material will be available on the website under Investors/Reports, Presentations.
Contact:
Lena Wange, IR & Communications Director
ir@orexo.com
+46 (0)18 780 88 00
About Orexo
Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to
For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.
This information was brought to you by Cision http://news.cision.com
View original content:https://www.prnewswire.com/news-releases/orexo-invitation-to-presentation-of-the-q2-2024-interim-report-302190767.html
SOURCE Orexo
FAQ
When will Orexo release its Q2 2024 Interim Report?
What time is Orexo's Q2 2024 report presentation?
Who will present Orexo's Q2 2024 report?
How can I attend Orexo's Q2 2024 report presentation?
Where can I find the presentation materials for Orexo's Q2 2024 report?
